Charles Schwab Investment Management Inc. Has $4.51 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Charles Schwab Investment Management Inc. raised its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 427,477 shares of the company’s stock after purchasing an additional 3,530 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.44% of ARS Pharmaceuticals worth $4,510,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SPRY. Compass Capital Corp MA ADV acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at $106,000. Quarry LP purchased a new stake in shares of ARS Pharmaceuticals during the 3rd quarter worth about $174,000. Stifel Financial Corp acquired a new stake in shares of ARS Pharmaceuticals during the 3rd quarter valued at about $199,000. Intech Investment Management LLC bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at approximately $239,000. Finally, SBI Securities Co. Ltd. bought a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $175,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on SPRY. Raymond James boosted their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Scotiabank started coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Leerink Partners raised their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $31.00.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now owns 7,696 shares of the company’s stock, valued at $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the transaction, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,589,359.26. This represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 159,600 shares of company stock worth $1,866,516. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $13.15 on Wednesday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -25.78 and a beta of 1.03. The firm has a fifty day moving average price of $12.13 and a two-hundred day moving average price of $13.07. ARS Pharmaceuticals, Inc. has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. As a group, sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.